Cocrystal Pharma Inc (COCP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cocrystal Pharma Inc (COCP) has a cash flow conversion efficiency ratio of -0.274x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.74 Million) by net assets ($6.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cocrystal Pharma Inc - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Cocrystal Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Cocrystal Pharma Inc (COCP) financial obligations for a breakdown of total debt and financial obligations.
Cocrystal Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cocrystal Pharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ozaurum Resources Ltd
AU:OZM
|
-0.323x |
|
Medifron DBT Co. Ltd
KQ:065650
|
-0.472x |
|
Austin Gold Corp
NYSE MKT:AUST
|
-0.013x |
|
NexgenRX Inc.
V:NXG
|
0.106x |
|
RONSHINE CH.HLD.HD-00001
F:1R7
|
N/A |
|
MK Trend Co. Ltd.
KO:069640
|
-0.361x |
|
CLEAN TEQ WATER LTD
F:9NK
|
N/A |
|
AztechWB Co. Ltd
KQ:032080
|
0.002x |
Annual Cash Flow Conversion Efficiency for Cocrystal Pharma Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Cocrystal Pharma Inc from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see Cocrystal Pharma Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.33 Million | $-8.19 Million | -1.294x | +25.25% |
| 2024-12-31 | $9.52 Million | $-16.48 Million | -1.731x | -211.42% |
| 2023-12-31 | $26.38 Million | $-14.67 Million | -0.556x | -2.61% |
| 2022-12-31 | $39.57 Million | $-21.43 Million | -0.542x | -230.30% |
| 2021-12-31 | $77.55 Million | $-12.72 Million | -0.164x | +12.40% |
| 2020-12-31 | $52.51 Million | $-9.83 Million | -0.187x | -207.94% |
| 2019-12-31 | $25.71 Million | $-1.56 Million | -0.061x | +50.94% |
| 2018-12-31 | $66.89 Million | $-8.29 Million | -0.124x | -89.24% |
| 2017-12-31 | $105.40 Million | $-6.90 Million | -0.065x | +54.27% |
| 2016-12-31 | $102.32 Million | $-14.65 Million | -0.143x | -132.67% |
| 2015-12-31 | $167.59 Million | $-10.32 Million | -0.062x | +93.19% |
| 2014-12-31 | $6.65 Million | $-6.01 Million | -0.903x | -219.17% |
| 2013-12-31 | $-6.03 Million | $-4.57 Million | 0.758x | +84.47% |
| 2012-12-31 | $-3.58 Million | $-1.47 Million | 0.411x | +170.34% |
| 2011-12-31 | $-2.77 Million | $-420.95K | 0.152x | +105.45% |
| 2010-12-31 | $6.93K | $-19.34K | -2.791x | -506.59% |
| 2009-12-31 | $54.54K | $-25.10K | -0.460x | -30.68% |
| 2008-12-31 | $95.34K | $-33.58K | -0.352x | -51.65% |
| 2007-12-31 | $147.13K | $-34.17K | -0.232x | -- |
About Cocrystal Pharma Inc
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C … Read more